News ESMO26: Halda buy delivers a win for J&J in prostate cancer A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.
News ESMO26: BMS dual-acting ADC beats chemo in breast cancer BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.
News ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.
News ESMO26: Neoadjuvant Enhertu fails in early breast cancer AstraZeneca and Daiichi Sankyo's Enhertu failed to show efficacy as neoadjuvant therapy for early-stage HER2-low breast cancer in the TALENT trial.
News ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.
News ESMO26: Tango sees 82% ORR with combo in pancreatic cancer A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.